Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Checked against the public recordLast updated Oct 2, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Other: Chemoradiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * At least 18 years of age * Histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation * Able to give written informed consent Exclusion Criteria: * Pregnant or breast-feeding * Prior treatment with anthracyclines * Radiation treatment not expected to involve any heart exposure as determined by treating provider * ECOG performance status greater than 2 * Vulnerable patients, including pregnant women and prisoners * Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of AlabamaBirmingham, Alabama
- The Brigham and Women's HospitalBoston, Massachusetts
- Washington University School of MedicineSt Louis, Missouri
- Rutger's University / Cancer Institute of New JerseyNew Brunswick, New Jersey
- Montefiore Medical CenterThe Bronx, New York
- Lancaster General HospitalLancaster, Pennsylvania
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
- Chester County HospitalWest Chester, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2025. Always confirm current availability with the study team.